1 / 60

Consigli durante la NIV

Guidelines and factors for successful NIV implementation in ARF, identifying patients, when to stop NIV, and predictors of failure. Importance of patient selection, monitoring, and when to consider ETI. Location guidance and staff familiarity for effective NIV use in hospitals.

annbradley
Download Presentation

Consigli durante la NIV

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Consigli durante la NIV M Vitacca Divisione di Pneumologia Fondazione S.Maugeri Lumezzane (BS) Italy

  2. Il momento e il paziente giusto

  3. Severe ARF Severity Mild To moderate Not established TO AVOID ETI TO PREVENT ALTERNATIVE to ETI Meaning of NIV use

  4. IDENTIFY PATIENTS (according to location ?) 1. Clinical abnormalities - moderate to severe dyspnea - RR > 24 b/min in COPD - RR > 30 – 35 b/min in AHRF - accessory muscle use, paradoxal breathing 2. Gas exchange abnormalities - PaCO2 > 45 mmHg, pH < 7.35 - PaO2/FiO2 < 250 mmHg Am J Respir Crit Care M d 2001; 163: 283-291; Intensive Care Medicine 2001; 27: 166-178

  5. COPD CHF/CPE PNA Asthma OHS NMD UAO post-op post-extub trauma ARDS MOF IPF Tight UAO

  6. the correct time to stop

  7. WEAK COUGH AND HYPER-SECRETIONS • SEVERE ENCEPHALOPATHY • INTOLERANCE AND AGITATION • PATIENT-VENTILATORY ASYNCHRONIES • EXCESSIVE LEAKS • DISCOMFORT • SLEEP DISTURBANCES • HYPERGLICAEMIA • LOW ADLs • POOR RESPONSE OF ABG AND RR • HIGH SCORES OF SEVERITY OF ILLNESS NEED OF ETI: range → 5-60% Courtesy of dott Scala

  8. BTS Guideline of NIMV in ARF Thorax 2002; 57: 192-211 Time to stop NIV for failure • no improvement or deterioration in consciousness • no improvement in ABG • severe complications • severe pneumonia on chest X-ray • 2° intrahospital failure with necessity of NIV • copiuos secretion • more than 18 continous hours of NIV for more than 4 days • nasal bridge erosion • intolerance to ventilator

  9. Perchè fallisce la NIV ? Perchè si sbaglia paziente Perchè non si rispettono le controindicazioni Perchè si sbaglio maschera Perchè si sbaglio modalità di ventilazione Perchè si sbaglio il settaggio Perchè il paziente non supporta più la NIV Perchè non miglioranono i gas Perchè vi è cattiva interazione con il ventilatore Perchè dà un senso di falsa sicurezza

  10. FATTORI PREDITTIVI PER IL FALLIMENTO DELLA NIV IN SOGGETTI CON INSUFFICIENZA RESPIRATORIA. A) Ipossiemici Ipercapnici Età Basso punteggio del livello di dipendenza misurato con scala ADL (activity daily life) Iperglicemia Presenza di polmonite come causa di insufficienza respiratoria acuta (IRA) Alto punteggio di gravità prognostica (alto APACHE II score all’ ammissione) Paziente incosciente, non collaborante Severa ipercapnia (paCO2 > 90 mmHg) Severa acidosi (pH a < 7.10) Mancanza di miglioramento (entro 1-2 h) degli scambi gassosi, frequenza cardiaca e respiratoria Paziente ipersecretivo Presenza di encefalopatia Intolleranza alla VMN Perdite di flusso dalla maschera Caduta della pressione arteriosa

  11. FATTORI PREDITTIVI PER IL FALLIMENTO DELLA NIV IN SOGGETTI CON INSUFFICIENZA RESPIRATORIA. B) Ipossiemici Normocapnici Età Alto punteggio di gravità prognostica (alto SAPS II score all’ ammissione) ARDS e polmonite come causa del ricovero Edema polmonare cardiogeno senza risposta alla terapia medica Mancato miglioramento della ossigenazione dopo VMN (1-2 h) Paziente ipersecretivo Presenza di encefalopatia Intolleranza alla VMN

  12. Be carefull ! NON INVASIVE RESPIRATORY SUPPORT IN HYPOXIEMIC ACUTE RESPIRATORY FAILURE ? • High percentage of failures • Late resolution • Difficult “invasive” diagnostic procedures (BAL, Brush) • Risk to delay ETI Take care of: • Accurate selection of the patients: - PaO2/FiO2 > 150 mmHg, - Lobar densities at chest X- Ray or CT - Absence of hemodynamic shock (BE > -2.5 mEq/L) • Empiric Antibiotic Treatment (Protocols !) • Non invasive fast diagnostic tests (Urinary antigens, etc.) • Hemocoltures • Don’t push to hard (stop NIV if PaO2/FiO2< 150 at 1-2 hrs)

  13. La giusta location

  14. BTS Equipment Recommendations Staff familiarity is key to success

  15. Timing is all… • Start early but not too early (Barbe study) • You are too late if… • Pt on verge of respiratory arrest • Pt severely hypoxaemic (PaO2/FiO2 < 75) • Pt comatose or hugely agitated • Medically unstable: acute MI, GI bleed, shock • What is your unit’s ‘door to mask’ time? • What are the main limitations? Simonds ERS school

  16. Location summary (1)

  17. Location summary (2)

  18. Il training adeguato

  19. Reasons for low use of NIV in acute hospitals: US survey No. of responses 20 10 0 Poor previous experience Hospital staff inadequately trained Equipment not appropriate Physicians lack of experience Other Maheshwari v et al Chest 2006:129: 1226-33

  20. Am J Respir Crit Care Med Vol 185, Iss. 2, pp 152–159, Jan 15, 2012 H admissions pts from NIV to EI N° pts NIV deaths

  21. Am J Respir Crit Care Med Vol 185, Iss. 2, pp 152–159, Jan 15, 2012 NIV and EI EI NIV no EI No support

  22. Monitoring: readyaccessto ETI and CPR Courtesy of dott Scala

  23. Monitoraggio

  24. Ventilatory Monitoring • Respiratory pattern • Pt-ventinteraction • Availabilityof ETI • in case of NIV failure Courtesy of dott Scala

  25. Monitoring • Clinical status, respiratory rate, heart rate, dyspnoea score, secretion clearance • Pulse oximetry • Continuous display of ECG and non-invasive BP • Arterial blood gases (ABG machine easily accessed) • Continuous non-invasive monitoring of CO2 helpful eg. Transcutaneous, end-tidal • Duration of NIV use • Ventilatory settings, FiO2, leak • Severity score • Side effects : skin integrity, GI, nasal symptoms • CXR, screening bloods etc. Simonds ERS school

  26. 100 – 75 % 49 -25 % 24 -0 % 74 -50 % Percentage of patients who fail NIV Eur Respir J 2005; 25:348-355

  27. Ventilatory Monitoring • Respiratory pattern • Pt-ventinteraction • Availabilityof ETI • in case of NIV failure

  28. YOU HAVE……. A VENTILATOR HAS NO BRAIN, BUT NEEDS TO COUPLE TWO BRAINS !

  29. Apparently there is nothing wrong on what you see on the ventilator With S. Navacourtesy

  30. But if you could see the neural activity of the patient….. With S. Navacourtesy

  31. 25 0 Ineffective effort Pao Pes 20 0 Sforzi inefficaci

  32. Un eccesso di supporto Con la cortesia del dott. Polese

  33. Totale desincronizzazione durante PSV Con la cortesia del dott. Polese

  34. Totale desincronizzazione durante PSV (perdite) Con la cortesia del dott. Polese

  35. Flow (l/sec) Vent. rate = 12 b/min Paw (cmH2O) Fr = 33 b/min Pes (cmH2O) 5 sec Time (sec) Triggering delay= Ineffective effort Georgopoulos et al. Intensive Care Med 2006

  36. Autotriggering Paw (cmH2O) 1) Low threshold for triggering 2) Dirt circuit 3) leaks Flow (l/sec) Pes (cmH2O) Time (sec) With ERS courtesy

  37. Flow Paw Pga Pes Pdi Expiratory asynchrony With ERS courtesy

  38. Controlla il setting diurno e notturno

  39. Bosma et al. Crit Care Med 2007;35:1048

  40. A CORRECT SETTING IS IMPERATIVE !

  41. Ventilatory Monitoring • Respiratory pattern • Pt-ventinteraction • Availabilityof ETI • in case of NIV failure

  42. Am J RespirCrit Care Med. 2001 Feb;163(2):540-77 Almost all the side effects of NIV are due to problems with interfaces

  43. 80-100% Air Leaks

  44. Monitor the tightness of the mask

  45. Types of Leaks Intentionalleaks Courtesy of dott Scala

  46. Look for a balance betweenleaks and comfort Courtesy of dott Scala

  47. Pressure sores

  48. Interface rotation strategy Conti G et al. RespirMed 2007; 52:1463-71 Girault C et al. Crit Care Med 2009; 37:124-31 Courtesy of dott Scala

More Related